Meniere Disease - Pipeline Review, H1 2020

February 2020 | 49 pages | ID: MA899F17EA8EN
Global Markets Direct

Abstracts

Meniere Disease - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meniere Disease - Pipeline Review, H1 2020, provides an overview of the Meniere Disease (Ear Nose Throat Disorders) pipeline landscape.

Meniere disease is a disorder of the inner ear that causes spontaneous episodes of vertigo. Signs and symptoms of Meniere disease are hearing loss, tinnitus and feeling of fullness in the ear. Causes include allergies, viral infection, head trauma and migraines.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meniere Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Meniere Disease (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 2, 1, 2 and 1 respectively.

Meniere Disease (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Meniere Disease (Ear Nose Throat Disorders).
• The pipeline guide reviews pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Meniere Disease (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Meniere Disease (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Meniere Disease (Ear Nose Throat Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Meniere Disease (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Meniere Disease - Overview
Meniere Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Meniere Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meniere Disease - Companies Involved in Therapeutics Development
IntraBio Ltd
Orbis Biosciences Inc
Otonomy Inc
Quark Pharmaceuticals Inc
Sound Pharmaceuticals Inc
Synphora AB
Meniere Disease - Drug Profiles
betamethasone valerate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ebselen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-2000s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPHL-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Meniere Disease - Dormant Projects
Meniere Disease - Product Development Milestones
Featured News & Press Releases
Sep 18, 2019: FDA grants Fast Track Designation for SPI-1005 in the treatment of Meniere's Disease
Jun 25, 2019: Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere's Disease clinical trial
Mar 20, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere's Disease clinical trial
Mar 06, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere's Disease clinical trial
Feb 06, 2019: Otonomy announces presentation on OTIVIDEX at Association for Research in Otolaryngology Annual Meeting
Oct 02, 2018: Otonomy announces OTIVIDEX data presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
Jul 26, 2018: Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX in Meniere Disease
Nov 08, 2017: Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX in Patients with M?ni?re's Disease
Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease
Aug 30, 2017: Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX in Patients with Menieres Disease
Jun 27, 2017: Sound Pharmaceuticals completes enrollment on Meniere's Disease clinical trial
Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere's Disease
Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
Jan 19, 2017: Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Meniere Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Meniere Disease - Pipeline by IntraBio Ltd, H1 2020
Meniere Disease - Pipeline by Orbis Biosciences Inc, H1 2020
Meniere Disease - Pipeline by Otonomy Inc, H1 2020
Meniere Disease - Pipeline by Quark Pharmaceuticals Inc, H1 2020
Meniere Disease - Pipeline by Sound Pharmaceuticals Inc, H1 2020
Meniere Disease - Pipeline by Synphora AB, H1 2020
Meniere Disease - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Meniere Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

IntraBio Ltd
Orbis Biosciences Inc
Otonomy Inc
Quark Pharmaceuticals Inc
Sound Pharmaceuticals Inc
Synphora AB